{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:53:55Z","timestamp":1791370435475,"version":"4.3.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R00CA277136"],"award-info":[{"award-number":["R00CA277136"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01645-1","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:26:35Z","timestamp":1791368795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-9777","authenticated-orcid":false,"given":"Hamlet","family":"Gasoyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2063-1876","authenticated-orcid":false,"given":"Michael B.","family":"Rothberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Kovach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-835X","authenticated-orcid":false,"given":"Nicholas J.","family":"Casacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1645_CR1","first-page":"111","volume":"75","author":"AH Saka","year":"2025","unstructured":"Saka AH, Giaquinto AN, McCullough LE, Tossas KY, Star J, Jemal A, et al. Cancer statistics for African American and Black people, 2025. CA Cancer J Clin. 2025;75:111\u201340.","journal-title":"CA Cancer J Clin"},{"key":"1645_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clml.2023.09.009","volume":"24","author":"J Mikhael","year":"2024","unstructured":"Mikhael J, Cichewicz A, Mearns ES, Girvan A, Pierre V, Rawashdh NA, et al. Overall survival in patients with multiple myeloma in the U.S.: a systematic literature review of racial disparities. Clin Lymphoma Myeloma Leuk. 2024;24:e1\u2013e12.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1645_CR3","doi-asserted-by":"publisher","unstructured":"Maclachlan KH, Papadimitriou M, Blaney P, Baughn LB, Shekarkhand T, Poos AM, et al. Genomic features do not account for differences in multiple myeloma risk by ancestry. Blood Cancer Discov. 2026. https:\/\/doi.org\/10.1158\/2643-3230.BCD-25-0259.","DOI":"10.1158\/2643-3230.BCD-25-0259"},{"key":"1645_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bglo.2025.100017","volume":"1","author":"E Tebuka","year":"2025","unstructured":"Tebuka E, Rambau P, Rasche L. Racial disparities in multiple myeloma. Blood Glob Hematol. 2025;1:100017.","journal-title":"Blood Glob Hematol"},{"key":"1645_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01379-6","volume":"15","author":"DE Mery","year":"2025","unstructured":"Mery DE, Tricot G, Al Hadidi S, Zhan Y, Ashby C, Bailey C, et al. Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans. Blood Cancer J. 2025;15:164.","journal-title":"Blood Cancer J"},{"key":"1645_CR6","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood.2019000406","volume":"133","author":"NR Fillmore","year":"2019","unstructured":"Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019;133:2615\u20138.","journal-title":"Blood"},{"key":"1645_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70309","volume":"7","author":"ER Wesley","year":"2026","unstructured":"Wesley ER, Anwer F, Rothberg MB, Kovach JD, Casacchia NJ, Peterre B, et al. Triplet or quadruplet regimen utilization and overall survival in patients diagnosed with multiple myeloma between 2017 and 2023. eJHaem. 2026;7:e70309.","journal-title":"eJHaem"},{"key":"1645_CR8","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMp1802313","volume":"378","author":"AJH Kind","year":"2018","unstructured":"Kind AJH, Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible \u2014 The Neighborhood Atlas. N Engl J Med. 2018;378:2456\u20138.","journal-title":"N Engl J Med"},{"key":"1645_CR9","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025;43:2739\u201351.","journal-title":"J Clin Oncol"},{"key":"1645_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01128-1","volume":"14","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan H, Anwer F, Kovach JD, Casacchia NJ, Wang M, Valent J, et al. Disparities in time to treatment with oral antimyeloma medications. Blood Cancer J. 2024;14:142.","journal-title":"Blood Cancer J"},{"key":"1645_CR11","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323:2417.","journal-title":"JAMA"},{"key":"1645_CR12","doi-asserted-by":"crossref","unstructured":"Gasoyan H, Anwer F, Casacchia NJ, Kovach JD, Valent J, Wang M, et al. Role of patient characteristics and insurance type in newly diagnosed multiple myeloma care disparities. JCO Oncol Pract. 2024;20:699\u2013707.","DOI":"10.1200\/OP.23.00672"},{"key":"1645_CR13","doi-asserted-by":"crossref","unstructured":"Gasoyan H, Fiala MA, Doering M, Vij R, Halpern M, Colditz GA. Disparities in multiple myeloma treatment patterns in the United States: a systematic review. Clin Lymphoma Myeloma Leuk. 2023;23:e420\u20137.","DOI":"10.1016\/j.clml.2023.08.008"},{"key":"1645_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01115-6","volume":"14","author":"M Mohty","year":"2024","unstructured":"Mohty M, Facon T, Malard F, Harousseau J-L. A roadmap towards improving outcomes in multiple myeloma. Blood Cancer J. 2024;14:135.","journal-title":"Blood Cancer J"},{"key":"1645_CR15","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/OP.24.00016","volume":"20","author":"MA Fiala","year":"2024","unstructured":"Fiala MA. Financial toxicity and willingness-to-pay for cancer treatment among people with multiple myeloma. JCO Oncol Pract. 2024;20:1263\u201371.","journal-title":"JCO Oncol Pract"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01645-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:26:37Z","timestamp":1791368797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01645-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01645-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"22 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FA has a consulting relationship with Bristol Myers Squibb Foundation, Caribou Biosciences, and received research funding (outside of this study) from Celgene (Inst), Bristol Myers Squibb (Inst), Primum, and Caribou Biosciences (Inst). MBR has a consulting relationship with Blue Cross Blue Shield Association. SR has a consulting relationship with Janssen, Nexcella Inc., Legend Biotech, and received research fundings from Janssen and Nexcella Inc. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the Cleveland Clinic Institutional Review Board as minimal risk research using data collected for routine clinical practice, for which the requirement for informed consent was waived (approval number: 22-1181). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval statement\/patient consent statement","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"173"}}